Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.vaccine.2009.11.054
Title: | Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children | Authors: | Lum, L.C.S. Borja-Tabora, C.F. Breiman, R.F. Brooks, W.A. Vesikari, T. Sablan, B.P. Chay, O.M. Tantracheewathorn, T. Schmitt, H.-J. Lau, Y.-L. Bowonkiratikachorn, P. Tam, J.S. Lee, B.W. Tan, K.K. Pejcz, J. Cha, S. Gutierrez-Brito, M. Kaltenis, P. Vertruyen, A. Czajka, H. Bojarskas, J. Cheng, S.-M. Rappaport, R. Baker, S. Gruber, W.C. Forrest, B.D. |
Keywords: | Combined vaccines Live attenuated influenza vaccine Measles-mumps-rubella vaccine Vaccine interference |
Issue Date: | 2010 | Citation: | Lum, L.C.S., Borja-Tabora, C.F., Breiman, R.F., Brooks, W.A., Vesikari, T., Sablan, B.P., Chay, O.M., Tantracheewathorn, T., Schmitt, H.-J., Lau, Y.-L., Bowonkiratikachorn, P., Tam, J.S., Lee, B.W., Tan, K.K., Pejcz, J., Cha, S., Gutierrez-Brito, M., Kaltenis, P., Vertruyen, A., Czajka, H., Bojarskas, J., Cheng, S.-M., Rappaport, R., Baker, S., Gruber, W.C., Forrest, B.D. (2010). Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 28 (6) : 1566-1574. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2009.11.054 | Abstract: | Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35 ± 7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV + Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively). © 2009 Elsevier Ltd. All rights reserved. | Source Title: | Vaccine | URI: | http://scholarbank.nus.edu.sg/handle/10635/25664 | ISSN: | 0264410X | DOI: | 10.1016/j.vaccine.2009.11.054 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.